Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: A multicenter retrospective study

Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials

11 p | 8 | 3

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis

10 p | 10 | 1